Insider Selling: GeneDx (NASDAQ:WGS) Director Sells 38,000 Shares of Stock

GeneDx Holdings Corp. (NASDAQ:WGS) Director Joshua Ruch sold 38,000 shares of the company’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $160.37, for a total transaction of $6,094,060.00. Following the sale, the director owned 11,941 shares in the company, valued at $1,914,978.17. The trade was a 76.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

GeneDx Stock Performance

WGS stock traded down $1.90 during midday trading on Wednesday, reaching $165.61. 495,723 shares of the company’s stock traded hands, compared to its average volume of 908,827. GeneDx Holdings Corp. has a 52 week low of $55.17 and a 52 week high of $170.75. The firm has a market capitalization of $4.79 billion, a PE ratio of 1,840.11 and a beta of 2.01. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.59 and a current ratio of 2.71. The company has a 50-day moving average price of $128.56 and a two-hundred day moving average price of $105.58.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings data on Tuesday, October 28th. The company reported $0.49 EPS for the quarter, beating the consensus estimate of $0.28 by $0.21. The company had revenue of $116.74 million during the quarter, compared to analysts’ expectations of $104.33 million. GeneDx had a net margin of 0.52% and a return on equity of 20.22%. GeneDx has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

Institutional Investors Weigh In On GeneDx

Institutional investors have recently bought and sold shares of the business. Jones Financial Companies Lllp boosted its stake in GeneDx by 664.3% in the 3rd quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock worth $25,000 after purchasing an additional 186 shares during the period. Quarry LP increased its position in shares of GeneDx by 248.8% during the 3rd quarter. Quarry LP now owns 293 shares of the company’s stock valued at $32,000 after purchasing an additional 209 shares during the last quarter. US Bancorp DE lifted its holdings in shares of GeneDx by 3,223.5% in the 1st quarter. US Bancorp DE now owns 565 shares of the company’s stock worth $50,000 after acquiring an additional 548 shares during the last quarter. Gordian Capital Singapore Pte Ltd bought a new stake in shares of GeneDx during the 3rd quarter worth approximately $65,000. Finally, AlphaQuest LLC grew its holdings in shares of GeneDx by 351.5% in the second quarter. AlphaQuest LLC now owns 763 shares of the company’s stock worth $70,000 after purchasing an additional 594 shares during the last quarter. Hedge funds and other institutional investors own 61.72% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on WGS shares. Wells Fargo & Company upped their target price on GeneDx from $95.00 to $140.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 4th. Piper Sandler boosted their price objective on shares of GeneDx from $120.00 to $140.00 and gave the company an “overweight” rating in a research report on Thursday, September 11th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of GeneDx in a research note on Wednesday, October 8th. Wall Street Zen downgraded GeneDx from a “buy” rating to a “hold” rating in a research note on Saturday, November 1st. Finally, Canaccord Genuity Group set a $160.00 price target on shares of GeneDx and gave the company a “buy” rating in a report on Wednesday, October 29th. Seven analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $129.22.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.